Compare AstraZeneca plc (AZN) vs Tapestry, Inc. (TPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Tapestry, Inc. — how do they compare? AstraZeneca plc trades at $166.9 (market cap $253.13B), while Tapestry, Inc. trades at $135.8 (market cap $27.35B). The key difference: AstraZeneca plc is far larger — about 9.3× Tapestry, Inc.'s market cap, and AstraZeneca plc pays the higher dividend (1.92%). Which is the better fit depends on your goals.
| AZN | TPR | |
|---|---|---|
Market Cap | $253.13B | $27.35B |
Sector | Health | Consumer Cyclical |
52-Week High | $209.48 | $160.49 |
52-Week Low | $137.44 | $95.69 |
Enterprise Value | $279.37B | $30.20B |
Dividend Yield | 1.92% | 1.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
TPR is trading at $136.13, down 3.27% today, with a bearish technical signal despite strong analyst support. The company shows impressive profitability with 76.18% gross margins and 55.74% ROE, though recent earnings declined significantly from $816M in 2024 to $183M in 2025. Recent quarters have consistently beaten EPS expectations, with Q1 2026 reporting $1.66 versus $1.30 expected.
The stock presents a compelling growth opportunity with 75.6% analyst buy ratings and a $184.14 consensus target, representing 35% upside. However, elevated P/E of 41.5 and recent net income contraction warrant caution. Key risks include high debt levels and competitive pressures in the luxury retail sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
